MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilson, A. L.
Right arrow Articles by Limbird, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, A. L.
Right arrow Articles by Limbird, L. E.

Monovalent cation and amiloride analog modulation of adrenergic ligand binding to the unglycosylated alpha 2B-adrenergic receptor subtype

AL Wilson, K Seibert, S Brandon, EJ Cragoe and LE Limbird

Department of Pharmacology, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232.

The unglycosylated alpha 2B subtype of the alpha 2-adrenergic receptor found in NG-108-15 cells possesses allosteric regulation of adrenergic ligand binding by monovalent cations and 5-amino-substituted amiloride analogs. These findings demonstrate that allosteric modulation of adrenergic ligand binding is not a property unique to the alpha 2A subtype. The observation that amiloride analogs as well as monovalent cations can modulate adrenergic ligand binding to the nonglycosylated alpha 2B subtype indicates that charge shielding due to carbohydrate moieties does not play a role in this allosteric modulation but, rather, these regulatory effects result from interactions of cations and amiloride analogs with the protein moiety of the receptor. Furthermore, the observation that both alpha 2A and alpha 2B receptor subtypes are modulated by amiloride analogs suggests that structural domains that are conserved between the two are likely to be involved in this allosteric modulation.

Volume 39, Issue 4, pp. 481-486, 04/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Ann. N. Y. Acad. Sci.Home page
D PINTHONG, D. KENDALL, and V. WILSON
Complex Interaction of a2-Adrenoceptor Binding Sites with Bovine Brain and Lung Extracts Containing Clonidine-Displacing Substance
Ann. N.Y. Acad. Sci., December 1, 2003; 1009(1): 216 - 221.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. E. Brady, Q. Wang, R. J. Colbran, P. B. Allen, P. Greengard, and L. E. Limbird
Spinophilin Stabilizes Cell Surface Expression of {alpha}2B-Adrenergic Receptors
J. Biol. Chem., August 22, 2003; 278(34): 32405 - 32412.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Christopoulos and T. Kenakin
G Protein-Coupled Receptor Allosterism and Complexing
Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. Yao, K. Asai, Z. Jiang, A. Ishii, P. Fan, A. S. Gordon, and I. Diamond
Dopamine D2 Receptor Inhibition of Adenylyl Cyclase Is Abolished by Acute Ethanol but Restored after Chronic Ethanol Exposure (Tolerance)
J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 833 - 839.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. A. Leppik, A. Mynett, S. Lazareno, and N. J. M. Birdsall
Allosteric Interactions between the Antagonist Prazosin and Amiloride Analogs at the Human alpha 1A-Adrenergic Receptor
Mol. Pharmacol., March 1, 2000; 57(3): 436 - 445.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
N. L. Schramm and L. E. Limbird
Stimulation of Mitogen-activated Protein Kinase by G Protein-coupled alpha 2-Adrenergic Receptors Does Not Require Agonist-elicited Endocytosis
J. Biol. Chem., August 27, 1999; 274(35): 24935 - 24940.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
H. GRENEY, F. HEEMSKERK, C. VONTHRON, C. MAGNIER, P. BOUSQUET, and M. DONTENWILL
Coexpression of Imidazoline Receptors and Alpha2-Adrenoceptors in Neuroglial Cell Line NG 108,15
Ann. N.Y. Acad. Sci., June 21, 1999; 881(1): 54 - 58.
[Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
T. W. Wilborn, D. Sun, and J. A. Schafer
Expression of multiple alpha -adrenoceptor isoforms in rat CCD
Am J Physiol Renal Physiol, July 1, 1998; 275(1): F111 - F118.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. A. Leppik, S. Lazareno, A. Mynett, and N. J. M. Birdsall
Characterization of the Allosteric Interactions between Antagonists and Amiloride Analogues at the Human alpha 2A-Adrenergic Receptor
Mol. Pharmacol., May 1, 1998; 53(5): 916 - 925.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. D. Okusa, L. Huang, A. Momose-Hotokezaka, L. P. Huynh, and A. J. Mangrum
Regulation of adenylyl cyclase in polarized renal epithelial cells by G protein-coupled receptors
Am J Physiol Renal Physiol, December 1, 1997; 273(6): F883 - F891.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Q. Yang, P. J. McDermott, E. Duzic, C. W. A. Pleij, J. D. Sherlock, and S. M. Lanier
The 3'-Untranslated Region of the alpha 2C-Adrenergic Receptor mRNA Impedes Translation of the Receptor Message
J. Biol. Chem., June 13, 1997; 272(24): 15466 - 15473.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Wozniak and L. E. Limbird
The Three alpha(2)-Adrenergic Receptor Subtypes Achieve Basolateral Localization in Madin-Darby Canine Kidney II Cells via Different Targeting Mechanisms
J. Biol. Chem., March 1, 1996; 271(9): 5017 - 5024.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics